The stakes are high and the bar continues to be raised for drug manufacturers, tasked with ensuring compliance and mitigating risk in an evolving, complex and rigorous reporting environment. Internal audit organizations carry a heavy burden amidst these challenges, often taking on an elevated role and presence within corporations.
CBI, the organizer of the life science industry’s highly acclaimed financial and compliance series events, is pleased to convene audit executives in September. Mark your calendar for a highly-focused and content-rich program, where internal audit teams learn ways to clear the latest compliance hurdles (aggregate spend reporting, fair market value, social media compliance, phishing vulnerability assessments, trade/wholesaler agreements), strategies for adding more value to the organization, approaches for auditing the organization’s global footprint, updates on the impact of healthcare reform, and much more.
